Australia’s TBG Diagnostics, a global molecular diagnostic company operating in the IVD industry, has formed a 60/40 joint venture with Haitou Group subsidiary, Xiamen Haicang Biotechnology Development.
The purpose of the joint venture is to build and operate a medical laboratory at TBG’s facility located within the Xiamen Biobay, a 10 square kilometer biomedicine industrial park home to more than 100 biomedical enterprises in Xiamen's Haicang district.
Both companies have committed to a total capital of Rmb30 million (US$4.5 million) for the joint venture with TBG contributing 60% and Xiamen Haicang 40%. The first stage investment of Rmb5 million will be used to build a 1,200 square meters laboratory and be located at TBG’s premises in the BioBay.
Construction will complete in May next year.